Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04340362 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04340362 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 16 participants.
The verdict
NCT04340362, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
Interventions
- DRUG VX-147
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-06-08 |
| Est. Completion | 2021-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04340362
The ClinicalTrials.gov registry entry for NCT04340362 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VX-147 is the first listed.
NCT04340362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04340362 about?
NCT04340362 is a clinical study titled "Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis". This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
What is the current status of trial NCT04340362?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2020-06-08. Estimated completion is 2021-12-09.
What interventions are being tested in trial NCT04340362?
The interventions under investigation include: VX-147 (DRUG).
Who is sponsoring clinical trial NCT04340362?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.